title: Exacerbation of radiation fibrosis with erlotinib: another pattern of radiation recall phenomenon.
abstract: A 79-year-old woman with advanced lung cancer presented with worsened radiation fibrosis after administration of erlotinib. After radiation therapy 7 months previously, she had radiation fibrosis that had been stable for months. On the 19th day after administration of erlotinib, low-grade fever and mild dyspnea developed accompanied by new pulmonary opacity in the area of the radiation fibrosis, which improved without therapy. We surmise that this is a manifestation of the radiation recall phenomenon, and discontinuation of the drug should be considered with discretion.
authors.affiliation: Department of Radiology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi 321-0293, Japan. arakawa@dokkyomed.ac.jp
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Arakawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Johkoh
authors.forename: Fumikazu
authors.initials: F
authors.lastname: Sakai
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kusumoto
authors.forename: Osamu
authors.initials: O
authors.lastname: Hataji
authors.forename: Osamu
authors.initials: O
authors.lastname: Taguchi
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*; D017564:Radiation Pneumonitis / Q000473:pathology*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride